Report : Asia Pacific Human Papillomavirus (HPV) Vaccine Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (9-valent HPV Vaccine, Quadrivalent HPV Vaccine, and Bivalent HPV Vaccine), Dosage (2 Dose and 3 Dose), Age (9 to 14 Years and 15 to 45 Years), Application (HPV-Attributable Cancer and Genital Warts), and End User (Doctors Office, Community Health Clinics, School-based Health Centers, Health Departments, Hospitals, and Others)
At 6.5% CAGR, the APAC Human Papillomavirus (HPV) Vaccine Market is speculated to be worth US$ 826.34 million by 2028, says The Insight Partners
According to Business Market Insights’ research, the APAC human papillomavirus (HPV) vaccine market was valued at US$ 567.57 million in 2022 and is expected to reach US$ 826.34 million by 2028, registering an annual growth rate of 6.5% from 2022 to 2028. Initiatives taken by health organizations and advancements in HPV diagnostics tests are the critical factors attributed to the market expansion.
Healthcare organizations have developed and adopted several strategies to prevent and eliminate HPV infections. The World Health Assembly, in August 2020, adopted the strategy for cervical cancer elimination. As per the strategy, to eliminate cervical cancer, all countries across the region must reach and maintain an incidence rate of below four per 100,000 women. To reduce the incidence rate of cervical cancer, countries should focus on vaccination, screening, and treatment of cervical cancer. In 2016, Gavi Board initiated an HPV vaccine program. That allows countries in their first year of the program to scale up and vaccinate girls between the age of 9 and 14 years. Through this new strategy, Gavi aimed to protect about 40 million girls from cervical cancer by 2020, preventing an estimated 900,000 deaths. Many countries accepted the Gavi support and introduced the HPV vaccine in their national immunization program. Countries with the highest burden of cervical cancer, initiated the Gavi HPV vaccine program. All these initiatives are aiding the HPV vaccines market substantially across the region.
On the contrary, high cost of HPV vaccines hurdles the growth of APAC human papillomavirus (HPV) vaccine market.
Based on type, the APAC human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. The quadrivalent HPV vaccine segment held 61.5% market share in 2022, amassing US$ 348.90 million. It is projected to garner US$ 506.60 million by 2028 to expand at 6.4% CAGR during 2022–2028.
Based on dosage, the APAC human papillomavirus (HPV) vaccine market is bifurcated into 2 dose and 3 dose. The 2 dose segment held 64.0% market share in 2022, amassing US$ 363.04 million. It is projected to garner US$ 525.58 million by 2028 to expand at 6.4% CAGR during 2022–2028.
Based on age, the APAC human papillomavirus (HPV) vaccine market is bifurcated into 9 to 14 years and 15 to 45 years. The 9 to 14 years segment held 75.1% market share in 2022, amassing US$ 426.21 million. It is projected to garner US$ 617.87 million by 2028 to expand at 6.4% CAGR during 2022–2028.
Based on application, the APAC human papillomavirus (HPV) vaccine market is bifurcated into HPV-attributable cancer and genital warts. The HPV-attributable cancer segment held 83.7% market share in 2022, amassing US$ 475.30 million. It is projected to garner US$ 698.66 million by 2028 to expand at 6.6% CAGR during 2022–2028.
Based on end user, the APAC human papillomavirus (HPV) vaccine market is segmented into doctors office, community health clinics, school-based health centers, health departments, hospitals, and others. The hospitals segment held 38.2% market share in 2022, amassing US$ 216.67 million. It is projected to garner US$ 311.30 million by 2028 to expand at 6.2% CAGR during 2022–2028.
Based on country, the APAC human papillomavirus (HPV) vaccine market has been categorized into China, Japan, India, Australia, Southeast Asia, New Zealand, South Korea, and rest of APAC. Our regional analysis states that China captured 28.8% market share in 2022. It was assessed at US$ 163.63 million in 2022 and is likely to hit US$ 228.81 million by 2028, exhibiting a CAGR of 5.7% during the forecast period.
Key players dominating the APAC human papillomavirus (HPV) vaccine market are ChengDu Institute of Biological Products Co., Ltd.; GlaxoSmithKline plc.; Inovio Pharmaceuticals; Merck & Co., Inc.; R-Pharm; Sanofi; Serum Institute of India Pvt. Ltd; Vaccitech; Walvax Biotechnology Co., Ltd.; and Xiamen Innovax Biotech CO., LTD. among othe
- In Feb 2021, QIAGEN and INOVIO Pharmaceuticals announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO's therapies.
- In May 2022, Serum Institute of India is developing a tetravalent HPV vaccine which includes L1 VLPs of serotypes 6,11,16,18, which is expected to give a coverage of approximately 90% against papilloma virus prevalent in the developing world. The vaccine is currently under development and will be available in the near future.
Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com